Eli Lilly's experimental obesity drug retatrutide achieved primary endpoints in late-stage trials, with the highest dose enabling patients to lose up to 28-30 percent of body weight in a once-weekly injection format.

Time

The Hill

An investigational obesity drug from Eli Lilly cleared important endpoints in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their body weight.  Lilly said that a once-weekly injection of retatrutide met the primary endpoint in a phase 3 clinical trial, as well as key secondary endpoints for obesity, delivering clinically meaningful weight loss.  The highest dose of retatrutide helped patients lose 28.3…